A prospective study of hepatitis B Vaccination â€" A comparison of responders versus nonresponders

Renal Failure

Volumn 33, Issue 3, 2011, Pages 276-279

  Brown, Catherine M ^a   Donlon, Sheila ^a   O'Kelly, Patrick ^a   Casey, Anne Marie ^a   Collier, Cathal ^a   Conlon, Peter J ^a   Walshe, John J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Engerix B ; ESRD patients; HBvaxPRO ; hemodialysis; hepatitis B vaccination

Indexed keywords

ALBUMIN; CALCIUM; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT HEPATITIS B VACCINE;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; EUROPE; FEMALE; GENDER; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; IMMUNITY; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; TREATMENT FAILURE; VASCULAR ACCESS;

AGED; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROLOGIC TESTS;

EID: 79952686666     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.559300     Document Type: Article

References (13)

1. Wong PN, Fung TT, Mak SK, et al. Hepatitis B virus infec-tion in dialysis patients. J Gastroenterol Hepatol. 2005;20 (11): 1641-1651.
2. Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68(5):2298-2303. (Pubitemid 43117807)
3. Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naïve and cen-tral memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70(2):371-376. (Pubitemid 44086588)
4. Agrawal S, Gollapudi P, Elahimehr R, Pahl MV, Vaziri ND. Effects of end-stage renal disease and hemodialysis on den-dritic cell subsets and basal and LPS-stimulated cytokine pro-duction. Nephrol Dial Transplant. 2010;25(3):737-746.
5. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant. 2010;25(1):205-212.
6. Chin AI. Hepatitis B virus vaccine response in hemodialysis baseline patient characteristics. Hemodial Int. 2003;7:296-303.
7. Thornton L, Fitzpatrick F, De La Harpe D, et al. Hepatitis B reactivation in an Irish dialysis unit, 2005. Euro Surveill. 2007;12(4):E7-E8
8. Centres for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodi-alysis patients. MMWR Recomm Rep. 2001;50(RR-5):1-43.
9. Dentico P, Crovari P, Lai PL, et al. Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titers. Vaccine. 2002;20(31-32):3725-3730. (Pubitemid 35223402)
10. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: The effect of age on immunological response to hepa-titis B vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2004;20(10):1053-1062. (Pubitemid 39657938)
11. Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemodial Int. 2005;9(4):367-375. (Pubitemid 41614648)
12. Beran J. Safety and immunogenicity of a new hepatitis B vac-cine for the protection of patients with renal insufficiency including pre-hemodialysis and hemodialysis patients. Expert Opin Biol Ther. 2008;8(2):235-247 (review). (Pubitemid 351233716)
13. Ocak S, Eskiocak AF. The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic hemodial-ysis patients and the use of tetanus toxoid. Nephrology (Carlton). 2008;13(6):487-491.